Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals

NGNEVery BearishCorporate Developmentsnews

High materiality9/10

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Nov 18, 2024, 10:38 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The 37.7% drop indicates significant loss of investor confidence, similar past cases lead to prolonged effects.

AI summary

What happened, with direct paths to the underlying reporting

Neurogene halted its high-dose gene therapy trial due to an adverse event. NGNE shares plunged 37.7% to $21.50 in pre-market trading. Other stocks also experienced declines in pre-market trading. Overall market futures were mixed, indicating market volatility.

Neurogene halted its high-dose gene therapy trial due to an adverse event.
NGNE shares plunged 37.7% to $21.50 in pre-market trading.
Other stocks also experienced declines in pre-market trading.
Overall market futures were mixed, indicating market volatility.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial